NCT00235352View on ClinicalTrials.gov

Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

April 30, 2005

Study Completion Date

February 28, 2007

Conditions
Schizophrenia
Interventions
DRUG

CX516 (Ampakine)

Trial Locations (1)

02114

Freedom Trail Clinic, Boston

All Listed Sponsors
collaborator

RespireRx

INDUSTRY

lead

North Suffolk Mental Health Association

OTHER

NCT00235352 - Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter